439 related articles for article (PubMed ID: 18239127)
1. Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis.
Asagiri M; Hirai T; Kunigami T; Kamano S; Gober HJ; Okamoto K; Nishikawa K; Latz E; Golenbock DT; Aoki K; Ohya K; Imai Y; Morishita Y; Miyazono K; Kato S; Saftig P; Takayanagi H
Science; 2008 Feb; 319(5863):624-7. PubMed ID: 18239127
[TBL] [Abstract][Full Text] [Related]
2. Immunology. The toll of cathepsin K deficiency.
Krieg AM; Lipford GB
Science; 2008 Feb; 319(5863):576-7. PubMed ID: 18239112
[No Abstract] [Full Text] [Related]
3. Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity.
Baugh M; Black D; Westwood P; Kinghorn E; McGregor K; Bruin J; Hamilton W; Dempster M; Claxton C; Cai J; Bennett J; Long C; McKinnon H; Vink P; den Hoed L; Gorecka M; Vora K; Grant E; Percival MD; Boots AM; van Lierop MJ
J Autoimmun; 2011 May; 36(3-4):201-9. PubMed ID: 21439785
[TBL] [Abstract][Full Text] [Related]
4. Induction of protective therapy for autoimmune diseases by targeted DNA vaccines encoding pro-inflammatory cytokines and chemokines.
Karin N
Curr Opin Mol Ther; 2004 Feb; 6(1):27-33. PubMed ID: 15011778
[TBL] [Abstract][Full Text] [Related]
5. Erosive arthritis in a patient with pycnodysostosis: an experiment of nature.
Ainola M; Valleala H; Nykänen P; Risteli J; Hanemaaijer R; Konttinen YT
Arthritis Rheum; 2008 Nov; 58(11):3394-401. PubMed ID: 18975331
[TBL] [Abstract][Full Text] [Related]
6. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys.
Kumar S; Dare L; Vasko-Moser JA; James IE; Blake SM; Rickard DJ; Hwang SM; Tomaszek T; Yamashita DS; Marquis RW; Oh H; Jeong JU; Veber DF; Gowen M; Lark MW; Stroup G
Bone; 2007 Jan; 40(1):122-31. PubMed ID: 16962401
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the kinetics of osteoclastogenesis in arthritic rats.
Schett G; Stolina M; Bolon B; Middleton S; Adlam M; Brown H; Zhu L; Feige U; Zack DJ
Arthritis Rheum; 2005 Oct; 52(10):3192-201. PubMed ID: 16200623
[TBL] [Abstract][Full Text] [Related]
8. S100A8 enhances osteoclastic bone resorption in vitro through activation of Toll-like receptor 4: implications for bone destruction in murine antigen-induced arthritis.
Grevers LC; de Vries TJ; Vogl T; Abdollahi-Roodsaz S; Sloetjes AW; Leenen PJ; Roth J; Everts V; van den Berg WB; van Lent PL
Arthritis Rheum; 2011 May; 63(5):1365-75. PubMed ID: 21337316
[TBL] [Abstract][Full Text] [Related]
9. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases.
Billiau A; Matthys P
J Leukoc Biol; 2001 Dec; 70(6):849-60. PubMed ID: 11739546
[TBL] [Abstract][Full Text] [Related]
10. Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells.
Sepulveda FE; Maschalidi S; Colisson R; Heslop L; Ghirelli C; Sakka E; Lennon-Duménil AM; Amigorena S; Cabanie L; Manoury B
Immunity; 2009 Nov; 31(5):737-48. PubMed ID: 19879164
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation.
Fissolo N; Kraus M; Reich M; Ayturan M; Overkleeft H; Driessen C; Weissert R
Eur J Immunol; 2008 Sep; 38(9):2401-11. PubMed ID: 18792018
[TBL] [Abstract][Full Text] [Related]
12. Cathepsin K inhibitor-polymer conjugates: potential drugs for the treatment of osteoporosis and rheumatoid arthritis.
Wang D; Li W; Pechar M; Kopecková P; Brömme D; Kopecek J
Int J Pharm; 2004 Jun; 277(1-2):73-9. PubMed ID: 15158970
[TBL] [Abstract][Full Text] [Related]
13. Nucleic acid recognizing Toll-like receptors and autoimmunity.
von Landenberg P; Bauer S
Curr Opin Immunol; 2007 Dec; 19(6):606-10. PubMed ID: 18060756
[TBL] [Abstract][Full Text] [Related]
14. Transgenic disruption of glucocorticoid signaling in mature osteoblasts and osteocytes attenuates K/BxN mouse serum-induced arthritis in vivo.
Buttgereit F; Zhou H; Kalak R; Gaber T; Spies CM; Huscher D; Straub RH; Modzelewski J; Dunstan CR; Seibel MJ
Arthritis Rheum; 2009 Jul; 60(7):1998-2007. PubMed ID: 19565501
[TBL] [Abstract][Full Text] [Related]
15. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics.
Yasuda Y; Kaleta J; Brömme D
Adv Drug Deliv Rev; 2005 May; 57(7):973-93. PubMed ID: 15876399
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cathepsin K reduces bone erosion, cartilage degradation and inflammation evoked by collagen-induced arthritis in mice.
Svelander L; Erlandsson-Harris H; Astner L; Grabowska U; Klareskog L; Lindstrom E; Hewitt E
Eur J Pharmacol; 2009 Jun; 613(1-3):155-62. PubMed ID: 19358841
[TBL] [Abstract][Full Text] [Related]
17. Cathepsin K deficiency partially inhibits, but does not prevent, bone destruction in human tumor necrosis factor-transgenic mice.
Schurigt U; Hummel KM; Petrow PK; Gajda M; Stöckigt R; Middel P; Zwerina J; Janik T; Bernhardt R; Schüler S; Scharnweber D; Beckmann F; Saftig P; Kollias G; Schett G; Wiederanders B; Bräuer R
Arthritis Rheum; 2008 Feb; 58(2):422-34. PubMed ID: 18240253
[TBL] [Abstract][Full Text] [Related]
18. Toll-like receptor homolog RP105 modulates the antigen-presenting cell function and regulates the development of collagen-induced arthritis.
Tada Y; Koarada S; Morito F; Mitamura M; Inoue H; Suematsu R; Ohta A; Miyake K; Nagasawa K
Arthritis Res Ther; 2008; 10(5):R121. PubMed ID: 18847495
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo immunopharmacological profile of Sch 40120.
Smith SR; Watnick AS; Kung T; Siegel MI
Immunopharmacol Immunotoxicol; 1993 Jan; 15(1):13-44. PubMed ID: 8450179
[TBL] [Abstract][Full Text] [Related]
20. Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors.
Katunuma N; Matsunaga Y; Himeno K; Hayashi Y
Biol Chem; 2003 Jun; 384(6):883-90. PubMed ID: 12887055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
